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t-PA promotes glomerular plasmin generation and matrix
degradation in experimental glomerulonephritis
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t-PA promotes glomerular plasmin generation and matrix de- merular diseases [1, 2]. Matrix overproduction, increased
gradation in experimental glomerulonephritis. matrix deposition, and decreased degradation all appear
Background. In addition to its well-known role in degrading to contribute to matrix accumulation [3, 4]. Although ourfibrin, recent evidence suggests that plasmin degrades matrix
understanding of the mechanisms underlying this processproteins and activates prometalloproteinases. Plasmin is gener-
has dramatically increased in recent years, research hasated from plasminogen by tissue plasminogen activator (t-PA).
We hypothesized that t-PA treatment increases plasmin gener- emphasized what increases matrix production and how
ation in nephritic glomeruli and degrades pathological matrix we can stop it. As a result, a number of promising thera-
leading to a therapeutic reduction in matrix accumulation. pies are on the horizon. However, even with a disease cure,Methods. Anti–Thy-1 nephritis was induced by injection of
normalization of matrix is likely to take many years.OX-7 antibody. Rats were given twice daily intravenous injec-
Diabetic patients with proven glomerulosclerosis whotions of saline (disease control group) or human recombinant
t-PA (rt-PA; 1 mg/kg body weight) on days 3 through 5. Pro- received a successful pancreas transplant took 10 years
teinuria, glomerular matrix protein staining, and glomerular to show significantly reduced matrix accumulation [5].
mRNA levels for transforming growth factor-b1 (TGF-b1), When patients present with rapidly progressing fibrosis,fibronectin, and plasminogen activator inhibitor type 1 (PAI-1)
such as those with HIV-associated nephropathy, organwere evaluated at day 6. Localization of rt-PA, plasmin genera-
failure may occur before the therapy takes effect. Intion by glomeruli in vitro, and glomerular production and con-
tent of active TGF-b1 were also investigated. these cases, it might be valuable to have therapies that
Results. Compared with disease control animals, proteinuria could quickly reduce accumulated matrix, just as many
and staining score for periodic acid-Schiff (2.75 6 0.17 vs. cancer therapies quickly reduce tumor load. Finally, the1.41 6 0.09), fibronectin-EDA1 (19 6 2 vs. 14 6 1), laminin
process of fibrosis is closely related to normal wound(35 6 2 vs. 25 6 2), type I collagen (33 6 1 vs. 21 6 3), and
type IV collagen (27 6 2 vs. 23 6 1) were significantly reduced repair [3]. In terms of evolution, it may be that wound
in treated rats (P , 0.01). Glomerular TGF-b1, fibronectin, repair was so important to survival that numerous back-
and PAI-1 mRNA levels were unchanged. rt-PA colocalized up mechanisms are built in. If this is the case, the related
with fibrin along glomerular capillary walls and in the mesan-
process of fibrosis may be difficult to stop with one thera-gium. Nephritic glomeruli in vitro had decreased plasmin activ-
peutic approach, and combinations of drugs may proveity, which was elevated by an in vivo presacrifice injection of
rt-PA. Glomerular production and content of active TGF-b1 extremely valuable. The present study takes an initial
were unchanged by the rt-PA injection. step to provide proof of the concept that enhancing ma-
Conclusions. These results show that injected rt-PA binds to trix degradation can be therapeutically efficacious.fibrin in nephritic glomeruli, thus increasing plasmin generation
Plasmin and metalloproteinases (MMPs) are consid-and promoting pathological matrix degradation without acti-
ered to play key roles in matrix degradation [4, 6, 7].vating latent TGF-b. Agents that increase plasmin generation,
such as t-PA, may have potential as antifibrotic therapies. Plasmin degrades matrix proteins fibronectin [8], laminin
[8], proteoglycan [9], and type IV collagen [10], as well
as fibrin. Plasmin also activates pro-MMP-1 (interstitial
Accumulation of extracellular matrix leading to glo- collagenase) [11] and pro-MMP-3 (stromelysin-1) [12].
merulosclerosis is a central feature of progressive glo- MMP-3 then potently activates pro-MMP-9 (gelatinase B)
[13], which in turn degrades collagenous proteins. Plas-
min is generated by the enzymatic activity of plasmino-Key words: tissue plasminogen activator, antifibrotic therapy, fibrin,
metalloproteinase, nephritic glomeruli, transforming growth factor-b. gen activators tissue-type (t-PA) and urokinase-type
(u-PA). PA activity is inhibited by plasminogen activatorReceived for publication August 8, 2000
inhibitors type 1 (PAI-1) and type 2 (PAI-2). Plasminand in revised form December 7, 2000
Accepted for publication January 11, 2001 generation is therefore the net result of the activity of
the plasminogen activators and the PAIs. That matrixÓ 2001 by the International Society of Nephrology
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degradation by cultured human mesangial cells depends logical matrix leading to a therapeutic reduction in ma-
trix accumulation.on PAI-1 levels was clearly shown when a monoclonal
antibody to PAI-1 was added and matrix degradation
increased fourfold [14].
METHODS
Cultured human mesangial cells can produce t-PA [15]
Materialsand u-PA [16]. In normal human glomeruli, t-PA exists
in the endothelium [17]. Tissue-PA binds to fibrin, and in Unless otherwise indicated, materials, chemicals, or
culture media were purchased from Sigma Chemical Co.doing so, its enzymatic activity is greatly increased [18].
Tissue-PA and fibrin are found to be associated and (St. Louis, MO, USA).
increased in many human glomerular diseases [19].
AnimalsOverexpression of transforming growth factor-b (TGF-b)
is the most common molecular feature of fibrotic renal The studies were performed in male Sprague-Dawley
rats (200 to 250 g) obtained from Sasco (Omaha, NE,diseases [1, 20]. In addition to stimulating matrix synthe-
sis and enhancing matrix-binding integrin expression, USA). Animal housing and care were in accordance with
the National Institutes of Health Guide for the Care andTGF-b inhibits matrix degradation [1, 3]. TGF-b1 mark-
edly increases PAI-1 production and potently inhibits Use of Laboratory animals (NIH publication number
85-23, 1985).plasmin generation and matrix degradation by cultured
human mesangial cells [21]. We have previously shown
Disease inductionthat PAI-1 synthesis dramatically increases and PA activ-
ity decreases when TGF-b1 is added to normal glomeruli Glomerulonephritis was induced by tail vein injection
of the monoclonal anti–Thy-1.1 antibody OX-7 (2.5 mg/kgin culture [22]. TGF-b1 also increases production of tis-
sue inhibitors of metalloproteinases (TIMPs) by cultured body weight) on day 0. The OX-7 monoclonal antibody
was produced in the ascitic fluid of adult female BALB/cmesangial cells [23, 24]. Isolated glomeruli from anti–
Thy-1 nephritis rats show decreased PA [22] and MMP mice as described previously [34].
activity [24, 25] in association with the overexpression
Time course of fibrinogen/fibrin staining inof TGF-b1. Finally, when neutralizing antibody to TGF-b
anti-Thy-1 nephritiswas administered to rats with Thy-1 nephritis, a dramatic
decrease in glomerular PAI-1 staining was observed [22]. Three rats were sacrificed as described later in this
article at each of eight time points from 0 to 28 daysAngiotensin II (Ang II) also participates in the control
of the PA-plasmin system by stimulating PAI-1 synthesis after OX-7 injection. Cortical tissue was stained for fi-
brinogen/fibrin staining as described later in this article.directly and through the induction of TGF-b [26, 27].
The glomerular content of Ang II increases in anti–Thy-1
rt-PA treatmentnephritis (abstract; Kanai et al, J Am Soc Nephrol 9:498A,
1998), and PAI-1 synthesis is decreased by Ang II block- A formulation of rt-PA suitable for injection into rats
was kindly provided by Genentech (South San Francisco,ade [27], a low-protein diet [28], and arginine supplemen-
tation [28] in this model. Recent studies have shown a CA, USA). rt-PA was administered intravenously by tail
vein injection twice a day from day 3 to day 5 at a dosereduction in PAI-1 overexpression in response to Ang
II blockade in radiation-induced nephropathy [29] and of 1 mg/kg body weight (N 5 6). Control rats received
an equal volume of saline (N 5 6).in aging [30].
Because increased Ang II, TGF-b, and PAI-1 are com-
Sacrificemon features of fibrotic renal diseases, it is likely that
inhibition of normal matrix degradation contributes sig- Rats were sacrificed at day 6. Rats were anesthetized
with ether. After blood was drawn from the lower ab-nificantly to the pathological process of matrix accumula-
tion [31–33]. It should be noted that currently used and dominal aorta, the kidney was perfused with 30 mL of
ice-cold phosphate-buffered saline (PBS) and harvested.future therapies aimed at reducing Ang II and/or TGF-b
would be expected to increase plasmin generation and For histologic examination, cortical tissue was snap fro-
zen and fixed in 10% neutral-buffered formalin. Glomer-matrix degradation through reductions in Ang II- and/or
TGF-b–induced increases in PAI-1 expression. The goal uli from individual rats were isolated by graded sieving
(150, 125, 106, and 75 mm mesh metal sieves) as describedof the present study was to determine the therapeutic
efficacy of treatment with an agent that was not expected previously [35].
to alter either Ang II or TGF-b levels, but only to en-
Light microscopyhance plasmin generation. We hypothesized that rt-PA,
injected into nephritic rats, would bind to glomerular Three micrometer sections of paraffin-embedded tis-
sue were stained with periodic acid-Schiff (PAS) andfibrin leading to increased glomerular plasmin genera-
tion. This plasmin would enhance degradation of patho- counterstained with hematoxylin. The total number of
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nuclei per glomerular cross section was calculated in 30 quent RNA extraction. For Northern analysis, RNA was
denatured and fractionated by electrophoresis through arandomly selected glomeruli per sample.
1.8% agarose gel (30 mg/lane) and transferred to a Hybond
Immunofluorescent staining for fibrinogen/fibrin nylon membrane (Amersham Corp., Little Chalfont, Buck-
inghamshire, UK). Nucleic acids were immobilized byThree micrometer frozen tissue sections were fixed in
48C ethyl alcohol for three minutes. After washing in ultraviolet irradiation. Membranes were prehybridized
with 50% formamide, 10% Denhardt’s solution, 0.1%PBS, FITC-conjugated rabbit anti-human fibrinogen/
fibrin antibody (Dako, Carpinteria, CA, USA) was incu- sodium dodecyl sulfate (SDS), 5 3 standard saline citrate
(SSC), and 200 mg/mL denatured salmon sperm DNA,bated at a 1:100 dilution for two hours at room tempera-
ture. Intraglomerular deposition of fibrinogen/fibrin was and hybridized with DNA probes labeled with 32P-dCTP
by random oligonucleotide priming (Boehringer Mann-semiquantitated by scoring 20 randomly selected glomer-
uli per section on a 0 to 4 scale as described previously heim Biochemicals, Indianapolis, IN, USA). The blots
were washed in 2 3 SSC, 0.1% SDS at room temperature[35, 36].
for 15 minutes and in 0.1 3 SSC, 0.1 SDS at 558C for
Immunoperoxidase staining for matrix proteins 30 minutes. DNA probes used were as follows: (1) rat
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)For indirect immunoperoxidase staining, three micro-
meter sections of formalin-fixed, paraffin-embedded tis- cDNA (a gift from Drs. P. Kondaiah and M.B. Sporn,
Dartmouth Medical School) [37], (2) TGF-b1 cDNAsue were incubated overnight at 48C with the following
antibodies: mouse anticellular fibronectin (fibronectin (kindly provided from Dr. D.L. Moses, Vanderbilt Can-
cer Center) [38], (3) fibronectin-EDA cDNA (a generousEDA1, 1:100 dilution; Chemicon, Temecula, CA, USA),
rabbit anti-mouse laminin (1:100 dilution; Cappel, Au- gift from Dr. R.O. Hynes, Massachusetts Institute of Tech-
nology) [39], and (4) PAI-1 cDNA (kindly provided byrola, OH, USA), rabbit anti-type I collagen (1:200 dilu-
tion; Rockland, Gilbertsville, PA, USA), and rabbit anti- Dr. T.D. Gelehrter, Michigan School of Medicine) [40].
type IV collagen (1:200 dilution; Rockland). The Dako
Urinary protein excretionEnvisione System peroxidase (Dako) was used for a
secondary antibody, and color was developed according Rats were housed in metabolic cages on day 5, and
24-hour urinary protein excretion was measured on urineto the manufacturer’s instructions.
collected by the Bradford method (Bio-Rad Protein
Image analysis of matrix accumulation Assay; Bio-Rad Laboratories, Hercules, CA, USA).
Quantitative measurement of glomerular area and
Double immunostaining for t-PA and fibrinogen/fibrinpositive staining area was performed on all experimental
rat tissues (N 5 6 per group). Three micrometer paraffin Two, day 3 nephritic rats were sacrificed 10 minutes after
rt-PA injection. The kidney was removed after perfusionsections of immunoperoxidase staining for fibronectin
EDA1, laminin, type I collagen, and type IV collagen with PBS as described previously in this article. Three
micrometer frozen tissue sections were fixed in 48C ethylwere subjected to computer image analysis. For each
section, 20 randomly selected glomeruli were evaluated, alcohol for three minutes. Staining was performed at
room temperature. First, rabbit anti-human recombinantand the mean index per section was calculated. The black
and white photographs of immunoperoxidase staining t-PA antibody (1:20 dilution; American Diagnostica Inc.,
Greenwich, CT, USA) was incubated with sections forwere scanned with a gray scale. The glomerular area
and positive staining area were processed with Adobe two hours, followed by TRITC-conjugated swine anti-
rabbit immunoglobulin (1:100 dilution; Dako) for onePhotoshop software. The glomerular area was selected
by tracing the border of Bowman’s capsule. The figure hour. Then after three washes in PBS, slides were incu-
bated with FITC-conjugated rabbit anti-human fibrino-obtained was changed to black by setting the output
level to 0. A binary figure of the positive staining area was gen/fibrin antibody (1:100 dilution; Dako) for two hours.
gained by setting the threshold so that the background
Plasmin activity of isolated glomerulistaining disappeared. The areas obtained were measured
with NIH image software, and then the percentage of Normal and day 3 nephritic rats were sacrificed 10 min-
utes after the injection of rt-PA or saline (N 5 4 forglomerular area with positive staining was calculated as
a staining index (%). each group). Intact glomeruli from individual rats were
isolated as described previously in this article. The plas-
RNA preparation and Northern hybridization min activity of isolated glomeruli was measured by chro-
mogenic substrate assay. Briefly, 1 3 104 freshly isolatedTotal RNA was extracted by a guanidinium isothiocy-
anate method using Trizol (GIBCO BRL, Grand Island, glomeruli were placed in 100 mL PBS and 20 mL of
3 mmol/L plasmin specific chromogenic substrate solu-NY, USA) according to the manufacturer’s instructions.
Isolated glomeruli from each rat were used for subse- tion (Tos-Gly-Pro-Lys-4-nitranilide-acetate; Chromozyme
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PL, Roche Molecular Biochemicals, Indianapolis, IN,
USA), and 100 mL of 100 mmol/L Tris-HCl buffer (pH 8.0)
were added. After one hour of incubation at room tem-
perature, glomerular supernatants were harvested. The
amount of p-nitroaniline released into supernatant by
glomeruli was measured at 405 nm with a microplate
reader. Standard curves were generated using porcine
plasmin (Sigma, St. Louis, MO, USA). Plasmin activity of
isolated glomeruli was expressed as 1024 U/104 glomeruli.
Measurement of glomerular TGF-b1 production
and content
Day 6 nephritic rats were sacrificed 10 minutes after
the injection of rt-PA (4 mg/kg body weight) or saline
Fig. 1. Time course of glomerular fibrinogen/fibrin staining in OX-7–(N 5 4 for each group). Glomeruli from individual rats induced nephritis. Data are from three rats at each time point. *P ,
were isolated as described previously in this article. For 0.01 vs. normal; #P , 0.01 vs. day 3.
measurement of glomerular production of TGF-b1, glo-
meruli were resuspended at 2 3 103 glomeruli/mL/well
in RPMI 1640 supplemented with 0.1 U/mL insulin,
hours until at least 28 days, fibrinogen/fibrin staining was100 U/mL penicillin, 100 mg/mL streptomycin, and
25 mmol/L HEPES buffer. After a 72-hour incubation significantly increased compared with normal animals
at 378C/5% CO2, the supernatant was harvested and (P , 0.01). This indicates that fibrin is present in the
stored at 2708C until analysis. For measurement of glo- diseased glomerulus to which injected rt-PA may bind.
merular content of TGF-b1, glomeruli were suspended Day 3 was chosen as the first treatment day because the
at 2 3 104 glomeruli/mL in PBS. Glomeruli were homog- injury phase of disease has passed and fibrin deposition
enized four times on ice by sonication. Each 15-second is dramatically increased.
sonication was followed by a 15-second cool down. After
centrifugation at 400 3 g for 10 minutes at 48C, the Effects of rt-PA treatment on matrix accumulation in
supernatant was stored at 2708C until analysis. Active anti–Thy-1 nephritis
TGF-b1 was measured without acid treatment of samples Representative glomeruli stained with PAS are shown
using an inhibitory enzyme-linked immunosorbent assay
in Figure 2. The glomeruli from the disease control rats(ELISA) kit (Quantikine; R&D Systems, Minneapolis,
showed marked accumulation of pathological matrix ex-MN, USA) according to the manufacturer’s instructions
pressed as PAS-positive material at day 6 (Fig. 2A). Theas described previously [27]. Total (active plus latent)
rt-PA–treated group showed reduced mesangial matrixTGF-b1 was measured after acid activation of culture
accumulation in comparison to the disease control groupsupernatant.
at day 6 (Fig. 2B). Figure 2C shows a graphical represen-
Statistics and calculation of percentage reduction in tation of PAS matrix scoring. PAS score increased from
disease severity 0.57 6 0.10 in normal control rats to 2.75 6 0.17 in
disease control rats as a result of nephritis. rt-PA injec-Data are expressed as mean 6 SD. The significance
of differences in the measured values between groups tion decreased the matrix score significantly (P , 0.001)
was analyzed by the Student t test or Welch t test. P , from 2.75 6 0.17 in the disease control group to 1.41 6
0.05 was considered statistically significant. The disease- 0.09 in the treated group. This represents a 62% reduc-
induced increase in a variable was defined as the mean tion in the disease-induced increase in the PAS staining
value for the disease control group minus the mean value score. Total glomerular cell counts of the rt-PA treated
of the normal control group. The percentage of reduction group were not different from those of the disease con-
in disease severity in a t-PA–treated group was calcu- trol group at day 6 (72 6 8 vs. 79 6 4).
lated as follows:
To evaluate the effect of rt-PA on fibrinogen/fibrin
deposition in nephritic glomeruli, direct immunofluo-1 2 1 Treated group mean 2 Normal control group meanDisease control group mean 2 Normal control group mean2 3 100
rescent staining was performed at day 6 (Fig. 3). The
staining score for fibrinogen/fibrin was reduced by 43%
RESULTS in the rt-PA treated group compared with the disease
Time course of fibrinogen/fibrin staining in control group (P , 0.01).
anti–Thy-1 nephritis Results of the image analysis of immunoperoxidase
staining for matrix proteins are shown in Figure 4. TheFigure 1 shows that glomerular fibrinogen/fibrin depo-
sition increases rapidly after OX-7 injection. From 12 percentage of glomerular area with positive staining was
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Fig. 3. Immunofluorescent staining score for fibrinogen/fibrin at day 6.
Glomerular staining for fibrinogen/fibrin was significantly lower in the
rt-PA treated group compared with the disease control group. *P ,
0.01 compared with disease control (N 5 6 rats per group).
levels of TGF-b1, fibronectin, and PAI-1 were unchanged
by rt-PA treatment.
Localization of administered rt-PA in
Fig. 2. Glomerular histology. Representative photomicrograph of glo- nephritic glomeruli
meruli from anti–Thy-1 rats treated with saline (A) or recombinant
To check the localization of administered rt-PA intissue plasminogen activator (rt-PA) (B) at day 6; (C) periodic acid-
Schiff (PAS) staining scores for each group is shown. rt-PA treatment nephritic glomeruli, double staining for t-PA and fibrin-
resulted in a highly significant reduction in PAS staining score compared ogen/fibrin was performed. Glomeruli from a disease
with disease control rats. *P , 0.001 vs. normal control; #P , 0.001 vs.
control rat showed weak staining for endogenous t-PAdisease control. Total glomerular cell counts did not differ between rt-
at day 3 (data not shown). Glomeruli from two rt-PA–PA–treated and disease control glomeruli (N 5 6 rats per group).
treated rats at day 3 showed intense staining for t-PA
(Fig. 7A), and this staining pattern was similar to that
of fibrinogen/fibrin (Fig. 7B). These findings suggest that
calculated as staining index for quantitative analysis. injected rt-PA colocalized with fibrinogen/fibrin along
the glomerular capillary loops and in the mesangium.Compared with the disease control group, the staining
index was significantly lower in the rt-PA–treated group
Effect of rt-PA on plasmin activity of glomeruliat day 6 for fibronectin-EDA1 (19 6 2 vs. 14 6 1, P , placed in culture
0.01), laminin (35 6 2 vs. 25 6 2, P , 0.01), type I
To evaluate the efficacy of rt-PA injection (1 mg/kgcollagen (33 6 1 vs. 21 6 3, P , 0.01), and type IV
body weight) on plasmin generation in glomeruli, wecollagen (27 6 2 vs. 23 6 1, P , 0.01). These represent
measured the plasmin activity of isolated glomeruli by
decreases in disease-induced matrix accumulation of chromogenic assay (Fig. 8). Day 3 nephritic glomeruli
36% for fibronectin-EDA1, 63% for laminin, 36% for placed in culture showed decreased plasmin activity com-
collagen I, and 50% for collagen IV. pared with normal rat glomeruli (8 6 1 vs. 11 6 1 3
1024 U/104 glomeruli, P , 0.01). Plasmin activity of the
Effect of rt-PA on urinary protein excretion in nephritic glomeruli was elevated by in vivo presacrifice
anti–Thy-1 nephritis injection of rt-PA (19 6 1 vs. 8 6 1, P , 0.01), whereas
the normal rat glomeruli did not show the significantTwenty-four–hour urinary protein excretion was mea-
increase in plasmin activity by the same presacrifice rt-sured from day 5 to day 6 (Fig. 5). Urinary protein excre-
PA treatment (12 6 1 vs. 11 6 1). rt-PA injection intotion was significantly lower in the rt-PA–treated group
nephritic rats resulted in plasmin activity that was 1.7-compared with the disease control group (46.5 6 15.6 vs.
fold higher than normal glomerular plasmin activity and76.6 6 9.2 mg/day, P , 0.01).
2.4-fold higher than that of nephritic glomeruli (Fig. 8).
Effect of rt-PA on glomerular mRNA Effect of rt-PA on TGF-b1 activation in
levels of TGF-b1, fibronectin, and PAI-1 in nephritic glomeruli
anti–Thy-1 nephritis Because plasmin has been shown to play a role in the
Glomerular RNA was isolated individually from each activation of latent TGF-b [41], we investigated glomeru-
lar production and content of active and total TGF-b1rat on day 6. As shown in Figure 6, glomerular mRNA
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Fig. 4. Image analysis of immunoperoxidase
staining for matrix proteins. Data present the
percentage of the glomerular area with posi-
tive staining. Glomerular staining for fibro-
nectin EDA1, laminin, type I collagen, and
type IV collagen were significantly lower in
the rt-PA–treated group at day 6. *P , 0.01
compared with disease control (N 5 6 rats per
group; 20 glomeruli per rat).
Fig. 5. Effect of rt-PA on 24-hour urinary protein excretion from day
5 to day 6. Urinary protein excretion was significantly lower in the
rt-PA–treated group. *P , 0.01 compared with disease control (N 5
6 rats per group).
Fig. 6. Effects of rt-PA on glomerular mRNA expression in anti–Thy-1
nephritis. (A) Representative Northern blot. The relative glomerularusing ELISA (Fig. 9). rt-PA was injected at fourfold the mRNA expression of TGF-b1, fibronectin, and PAI-1 is depicted in
dose used in other parts of this study to enhance any panels B, C, and D, respectively, for data on all blots (N 5 6 rats per
group). Glomerular mRNA levels of TGF-b1, fibronectin, and PAI-1TGF-b1 activation that might be occurring. Day 6 was
were unchanged at day 6.also the peak of fibrin deposition (Fig. 1) and TGF-b1
expression in the model (data not shown). Rats were
sacrificed 10 minutes after rt-PA injection (4 mg/kg body
weight) on day 6, and glomeruli were isolated and either glomeruli. In one day 6 rat, the 4 mg/kg body weight
dose of rt-PA was injected. One day 6 disease controlsonicated to determine the glomerular content of
TGF-b1 or placed in culture for 72 hours to assess the rat served as the control. Glomeruli were isolated, and
glomerular plasmin generation was measured as de-glomerular production of TGF-b1. rt-PA treatment did
not affect the glomerular production of total TGF-b1 scribed previously in this article. A fivefold increase in
plasmin generation by nephritic glomeruli compared(455 6 118 vs. 521 6 102 pg/2 3 103 glomeruli/72 hours)
or active TGF-b1 (5.6 6 1.0 vs. 5.9 6 0.3). rt-PA treat- with normal glomeruli was seen (37.0 vs. 7.5 3 1024 U/
104 glomeruli), suggesting that at this dose, plasmin gen-ment also did not affect total TGF-b1 (919 6 280 vs.
922 6 272 pg/2 3 104 glomeruli) or active TGF-b1 (7.1 6 eration is greatly increased but does not lead to increased
activation of latent TGF-b1.2.3 vs. 6.7 6 0.9) in supernatant from sonicated, fresh
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Fig. 7. Representative immunofluorescent staining for fibrinogen/fibrin
(A) and t-PA (B). Disease control rats showed weak staining for endoge-
nous t-PA at day 3 (data not shown). (A and B) Double staining of a
glomerulus from an rt-PA treated rat at day 3. Injected rt-PA colocalized
with fibrinogen/fibrin along the capillary loops and in the mesangium.
Sections from two disease control and two rt-PA–treated rats were
Fig. 8. Effect of rt-PA on the glomerular plasmin activity of normalexamined.
and diseased (day 3) rats. Kidneys were removed 10 minutes after saline
or rt-PA injection (1 mg/kg body weight). Nephritic glomeruli placed
in culture had decreased plasmin activity, which was elevated by in vivo
presacrifice injection of rt-PA (day 3, left and right bar, respectively;
N 5 4 rats per group). *P , 0.01 compared with normal rats; #P ,DISCUSSION
0.01 compared with disease control.
In anti–Thy-1 nephritis, fibrin deposition occurs along
the glomerular capillary walls and in the mesangium.
The time course of fibrinogen/fibrin staining shown in
Figure 1 indicates that there is a great deal of fibrin to growth factors from the disease setting did not contribute
to the decrease in matrix accumulation is the finding thatwhich injected rt-PA can bind during the day 3 to day 5
treatment period. In addition to its high affinity for fibrin, glomerular mRNA levels for key mediators of disease
were not altered at day 6 (Fig. 6). If the action of growtht-PA’s affinity for substrate plasminogen increases when
it binds to fibrin. This binding increases the availability factors released from the fibrin clot were eliminated by
fibrin degradation, one would expect disease to be dimin-of plasminogen locally, which results in more efficient
(several hundred-fold) activation of plasminogen at the ished and to be reflected in lower mRNA levels for
TGF-b1, fibronectin, and PAI-1. This did not occur. Itfibrin surface [42]. Double immunostaining of t-PA and
fibrinogen/fibrin showed colocalization in nephritic rat is possible that the administration of rt-PA from a time
earlier than day 3 might produce a reduction in diseaseglomeruli (Fig. 7). Furthermore, glomerular plasmin ac-
tivity was elevated only when rt-PA was injected into severity, as reflected by a reduction in mRNA levels.
Antifibrotic effects of a mixture of orally administerednephritic rats and not when injected into normal rats
with trace fibrinogen/fibrin staining (Fig. 8). These data proteases have been reported in a number of experimen-
tal renal diseases [44, 45]. The mechanism(s) of thesestrongly suggest that when rt-PA is injected into ne-
phritic rats from day 3 to day 5 of disease, the rt-PA is effects is unclear, but increased clearance of TGF-b by
protease/a2-macroglobulin complexes and immunomo-targeted to the glomerulus by fibrin that is present as
part of the response to injury, and when bound to fibrin, dulation by these proteases have been suggested [46, 47].
Zoja et al have demonstrated that rt-PA treatment de-rt-PA’s affinity for plasminogen increases resulting in
plasmin generation. creased fibrin deposition and crescent formation in rabbit
antiglomerular basement membrane nephritis [48]. Oth-The therapeutic consequences of this increased plas-
min were (1) highly significant decreases in PAS-positive ers found decreased expression of t-PA and increased
PAI-1 in anti-glomerular basement membrane (anti-material (Fig. 2); (2) decreased fibrinogen/fibrin accumu-
lation (Fig. 3); (3) decreased accumulation of specific GBM) nephritis that was associated with reduced fi-
brinolytic activity [49]. In these studies, it was assumedmatrix proteins fibronectin EDA1, laminin, type I colla-
gen, and type IV collagen (Fig. 4); and (4) decreased that the therapeutic effect arose directly from increased
fibrinolysis. However, there have been many disappoint-proteinuria (Fig. 5). It is uncertain exactly what the se-
quence of events from increased plasmin generation to ing attempts to reduce disease severity by inhibiting co-
agulation, leading some to conclude that rather thandecreased matrix accumulation is in this setting. It is
possible that plasmin degraded primarily fibrin. Fibrin contributing to glomerular injury, coagulation is a sec-
ondary phenomenon [50]. In addition, none of theseclot is rich in platelets, and platelets are rich in platelet-
derived growth factor and TGF-b [43]. It is possible studies asked whether the therapeutic effect observed
could be due to direct degradation of matrix by increas-that during fibrin degradation, these growth factors are
inactivated and do not contribute to disease to the extent ing plasmin or other proteases, as our data suggest.
Although the mechanism of activation of TGF-b inthat they normally do. Arguing against this is the fact
that treatment was started at day 3, relatively late in the vivo is poorly understood [41, 51], it has been shown that
plasmin activates TGF-b in vitro [41]. We found that adisease course. Stronger evidence that inactivation of
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Fig. 9. Effect of rt-PA on glomerular produc-
tion and glomerular content of total and active
TGF-b1. Kidneys were removed 10 minutes
after saline or rt-PA injection (4 mg/kg body
wt) at day 6 (N 5 4 for each group). The glo-
merular production of total TGF-b1 (A) and
active TGF-b1 (B) and the glomerular content
of total TGF-b1 (C) and active TGF-b1 (D)
were unchanged by rt-PA treatment.
large dose of rt-PA injected into a day 6 nephritic animal Fibrin deposition in the mesangium and the endothe-
yielded a fivefold increase in glomerular plasmin genera- lium has been observed in a number of human glomeru-
tion. When this dose was injected into other day 6 ne- lar diseases, including IgA nephropathy [19, 58], Hen-
phritic animals, active TGF-b did not increase. These och-Sho¨nlein purpura nephritis [58], and lupus nephritis
results suggest that increased plasmin alone is not suffi- [19, 59]. Although rt-PA treatment might be efficacious
cient to activate the latent TGF-b produced by nephritic in reducing matrix accumulation, rt-PA may cause systemic
glomeruli. This conclusion cannot be a certainty, how- fibrinolysis and therefore may present a bleeding risk [60].
ever, since the ELISA kit used to assay active TGF-b is We envision that if chronic administration of rt-PA were
not specifically designed for measuring active TGF-b in necessary to reduce matrix, smaller doses or the develop-
nonacidified samples. Also, the values obtained for ac- ment of methods for local delivery would be necessary.
tive TGF-b before acidification (to activate all TGF-b In conclusion, this study demonstrates that rt-PA treat-
for measurement of total values) are at the lower limits ment attenuates the glomerular accumulation of fibrin,
of sensitivity for the assay. Nonetheless, recent data in fibronectin, laminin, type I collagen, and type IV collagen
the bleomycin model of pulmonary fibrosis suggest that and decreases proteinuria without changing mRNA lev-
a number of factors are required for activation of TGF-b els of TGF-b, PAI-1, and fibronectin in anti–Thy-1 ne-
in vivo [52]. It is also likely that a substantial increase phritis. rt-PA and fibrin colocalize in nephritic glomeruli.
in active TGF-b would have increased disease severity Plasmin activity of nephritic glomeruli is elevated by a
to a detectable level. As demonstrated by all of the dis- presacrifice injection of rt-PA, but we find no evidence
ease measures employed, this did not occur.
for increased activation of latent TGF-b.Recombinant tissue plasminogen activator decreased
These results suggest that injected rt-PA binds fibrinproteinuria in this study. The mechanism of this effect
in nephritic glomeruli, where it increases plasmin gen-is uncertain but may be due to decreased glomerular
eration and promotes pathological matrix degradation.matrix accumulation. A direct effect of plasmin on pro-
While rt-PA may have limited applicability in human fi-teinuria would have been expected to have the opposite
brotic disease, these results show that therapeutic strate-effect since elastin and cathepsin G have been reported
gies aimed at increasing matrix degradation may haveto increase urinary protein excretion [53].
great therapeutic potential.We measured glomerular cellularity in this study be-
cause it has been reported that MMPs have a mitogenic
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